Replies to post #94806 on Biotech Values

[genisi]

I think that Aricept does not have Hatch-Waxman data exclusivity protection anymore. Teva filed ANDA on Oct, 2004, with Para IV certification against ‘864, ‘321, ‘911, ‘760 and Para III against patent ‘841. Later, in Oct, 2005, Teva amended it’s ANDA with Para IV against patent ‘841 (the only one that Eisai is defending). Due to Para IV filing against product patent, Teva also got First Filer status.